Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4470159
Max Phase: Preclinical
Molecular Formula: C10H8ClN3O2
Molecular Weight: 237.65
Molecule Type: Unknown
Associated Items:
ID: ALA4470159
Max Phase: Preclinical
Molecular Formula: C10H8ClN3O2
Molecular Weight: 237.65
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(O)c1cn(Cc2ccccc2Cl)nn1
Standard InChI: InChI=1S/C10H8ClN3O2/c11-8-4-2-1-3-7(8)5-14-6-9(10(15)16)12-13-14/h1-4,6H,5H2,(H,15,16)
Standard InChI Key: TVDRLUFPNNVBEC-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 237.65 | Molecular Weight (Monoisotopic): 237.0305 | AlogP: 1.68 | #Rotatable Bonds: 3 |
Polar Surface Area: 68.01 | Molecular Species: ACID | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 3.02 | CX Basic pKa: | CX LogP: 2.39 | CX LogD: -1.08 |
Aromatic Rings: 2 | Heavy Atoms: 16 | QED Weighted: 0.88 | Np Likeness Score: -2.28 |
1. Hussein WM, Feder D, Schenk G, Schenk G, Guddat LW, McGeary RP.. (2019) Synthesis and evaluation of novel purple acid phosphatase inhibitors., 10 (1): [PMID:30774855] [10.1039/C8MD00491A] |
Source(1):